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S UMMA R Y
Mathematical modelling is commonly used to evaluate
policy options for tuberculosis (TB) control in high-
burden countries. Although major policy and funding
decisions are made based on these analyses, there is
concern about the variability of results produced using
modelled policy analyses. We discuss new guidance for
country-level TB policy modelling. The guidance was
developed by the TB Modelling and Analysis Consor-
tium in collaboration with the World Health Organiza-
tion Global TB Programme, with input from a range of
TB stakeholders (funders, modelling groups, country TB
programme staff and subject matter experts). The
guidance describes principles for country-level TB
modelling, as well as good practices for operationalising
the principles. The principles cover technical concerns
such as model design, parameterisation and validation,
as well as approaches for incorporating modelling into
country-led policy making and budgeting. For model-
lers, this guidance suggests approaches to improve the
quality and relevance of modelling undertaken to
support country-level planning. For non-modellers, this
guidance describes considerations for engaging model-
ling technical assistance, contributing to a modelling
exercise and reviewing the results of modelled analyses.
If routinely adopted, this guidance should improve the
reliability, transparency and usefulness of modelling for
country-level TB policy making. However, this guidance
will not address all challenges facing modelling, and
ongoing work is needed to improve the empirical
evidence base for TB policy evaluation and develop
stronger mechanisms for validating models. Increasing
country ownership of the modelling process remains a
challenge, requiring sustained engagement and capacity
building.
K E Y WORD S : guidance; country-level; resource alloca-
tion; mathematical modeling
MATHEMATICAL MODELLING is commonly
used to evaluate disease control options in high-
burden settings. In several recent examples, mathe-
matical modelling has been used to guide major
policy changes, including revisions to human immu-
nodeficiency virus (HIV) treatment guidelines,1,2 and
South Africa’s recent development of an investment
framework for tuberculosis (TB) and HIV.3–5 An
increasing number of applications to international TB
programme funders now use modelling to justify
funding requests, which has been actively promoted
by funding and technical agencies. By January 2018,
more than 20 low- and middle-income countries had
used modelling to inform Global Fund applications,
National Strategic Plans or other domestic budgetary
or policy processes. Modelling also shapes broader
policy discussions,6 and there are proposals that
modelling evidence be formally considered during
World Health Organization (WHO) guideline devel-
opment.7
While models are increasingly used for prospective
policy evaluation, it can be difficult for the audience
for modelling results (country policy makers, funders)
to understand whether modelling results are correct,
or how the appropriateness of modelling should be
judged.8 Moreover, there is increasing concern about
the variability of results produced using these
analyses, with several recent model comparison
exercises demonstrating that different models can
produce very different results, even when examining
standardised policy questions.9–13 When model nat-
ural history assumptions have been compared against
empirical data, these comparisons have shown wide
variation between models and systematic deviations
from the empirical evidence.14,15 Ideally, models
would be judged by their ability to predict future
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outcomes,16 yet when this predictive validation has
been possible, results have been mixed.17 In a key
example, modelling undertaken before adoption of
the XpertwMTB/RIF (Cepheid, Sunnyvale, CA, USA)
assay for TB diagnosis in South Africa suggested
substantial health impact and attractive cost-effec-
tiveness for Xpert-based diagnostic algorithms.18–20
However, subsequent pragmatic trials21 and an
evaluation of South Africa’s national Xpert roll-
out22 demonstrated only a modest impact on
diagnosis and no statistically discernable impact on
mortality. Subsequent cost-effectiveness analyses
showed substantially diminished impact esti-
mates.23,24
Based on these concerns, a collaboration of
international scientific and policy stakeholders has
developed principles and good practices for country-
level TB modelling. This work was led by the TB
Modelling and Analysis Consortium (TB MAC), in
collaboration with the WHOGlobal TB Department,
representatives of major funders and technical
partners (The Global Fund, the World Bank, the Bill
and Melinda Gates Foundation, the US Agency for
International Development, the Stop TB Partnership),
leading modelling groups, technical experts and
country-level TB programme representatives. The
guidance is published by the WHO Global Task
Force on TB Impact Measurement.
In the present paper, we describe the process of
developing the modelling guidance (Methods section)
and report on the modelling principles included in
this guidance (Results section). In the Discussion, we
discuss the role that this modelling guidance can play
in the expanding field of country-level TB modelling,
identify current challenges for country-level TB
modelling and propose additional actions that could
improve the rigour and usefulness of modelling to
support TB policy making.
METHODS
Scope
The guidance was developed 1) to describe the
appropriate use of mathematical models to support
national TB policy and planning, including applica-
tions to international funding agencies, 2) to consider
both epidemiological and economic aspects of mod-
elling, to address all considerations for evaluating
competing policy options (e.g., projecting future
epidemiological outcomes, cost estimation, analyses
of cost-effectiveness and allocative efficiency), and 3)
to consider the technical aspects of modelling, as well
as the approaches used to apply modelling in a given
country, and integrate modelling evidence into
decision-making. The guidance was developed to be
read in conjunction with other relevant guidance
documents, such as the Gates Reference Case for
Economic Evaluation,25 and additional criteria pre-
scribed by funders or other stakeholders.
Target audience
The target audience is the participants and stake-
holders in country-level TB modelling. This includes
individuals who build and/or apply models, policy
makers, technical experts, international funding and
technical partners, and other individuals and organi-
sations that support TB policy making. For modellers,
the guidance suggests approaches to improve the
quality, relevance, transparency and timeliness of
modelling. For non-modellers, this guidance de-
scribes considerations when engaging modelling
technical assistance, contributing to a modelling
exercise or reviewing the results of modelled analyses.
Development process
An initial outline was prepared by a small writing
committee and reviewed by 30 expert stakeholders,
including TB modellers, country stakeholders, donors
and advocates. Suggestions were incorporated and a
full draft of the guidance developed. Following a
further round of review, the draft guidance was
presented at the TB MAC annual meeting in Glion,
Switzerland (18–22 September 2017), where input
was invited from a wider stakeholder group that
included modelling groups, international stakehold-
ers and funders and other technical experts. Further
input was provided after this meeting by country
stakeholders and technical experts, and a final draft
reviewed and endorsed by the WHO Global Task
Force on TB Impact Measurement in May 2018.
Format
The guidance is organised as 10 principles to guide
country-level TB modelling. These principles were
designed to be general enough to apply to the
majority of scenarios that arise in a modelling
application. For each principle, a number of ‘good
practices’ were developed. While unlikely to apply to
all situations, these practices suggest concrete actions
for operationalising each principle.
Role of the funding source
Employees of the funder participated during guidance
development discussions. The funder had no role in
manuscript development or submission decisions.
RESULTS
The 10 principles for country-level TB modelling are
described below. These principles were endorsed by
the WHO Global Taskforce on TB Impact Measure-
ment, and included the published guidance,26 which
can be found at http://www.who.int/tb/publications/
2018/country_modelling/en/.
Table 1 provides a summary description, and the
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Figure shows how these principles relate to the steps
of a typical modelling application. Good practices for
each principle are provided in the supplement, and
the guidance document also provides examples from
country-modelling applications indicating when and
how the principles would apply.
Principle 1: relevance
Modelling should assess the policies and outcomes
relevant to the decision maker. Without good
collaboration between the users and producers of
modelling information, it is all too easy for modelling
to evaluate strategies that differ from those being
considered by decision makers. Where a pre-existing
model is used for a new planning exercise, the model
may be insufficiently tailored to the local context or
strategies may be excluded from consideration
because they are not already built into the model.
Ideally, the modelling exercise can play a beneficial
role in shaping the policy scenarios being considered
and identifying outcomes of interest, with the
specificity required to parameterise a model forcing
participants to think through the details of how a
policy or new intervention would be implemented,
the mechanisms through which it would impact costs
and health outcomes, and how these should be
summarised to inform the decision.
Principle 2: realism
Modelling should explicitly consider implementation
challenges that may reduce policy effectiveness or
increase policy costs, and examine the plausibility of
assumptions required for policy success. Modelling is
often called upon to evaluate novel interventions or
proposals to expand the coverage or quality of
routine services above current levels. For these
scenarios, there is generally less information about
their effects and costs in typical programmatic
settings. This can produce overly optimistic projec-
tions of the effectiveness or cost-effectiveness of
proposed policies, particularly when initial evidence
is obtained in high-capacity clinical settings or for
subpopulations where effect sizes are larger, or when
there is external pressure for modelling to ‘be
ambitious’. Historical experience is likely to be the
best starting point for modelling assumptions about
the pace and success of implementation.
Principle 3: appropriateness of model structure
The model design should be justified in terms of the
questions and context being considered—the struc-
ture should be sufficiently detailed to represent the
mechanisms generating outcomes, but avoid unnec-
essary complexity. Model development commonly
requires many decisions about model structure,
dealing with how to represent the population affected
by a particular policy and how to describe their
transition through demographic and epidemiological
processes and the receipt of health care. These choices
balance the conflicting priorities of 1) faithfully
representing the process being modelled, which
commonly leads to more detailed modelling ap-
proaches (e.g., greater heterogeneity of the modelled
population or more complicated functions describing
health state transitions), and 2) developing a model
whose processes are transparent and understandable
for both the modeller and the modelling audience,
which may be facilitated by simpler modelling
approaches. While there will be some structural
choices that promote both of these aims simulta-
neously, most choices involve a trade-off between
realism and parsimony. Moreover, the decision to add
more detail on a particular part of the model will not
necessarily improve the validity of the results—as
model complexity increases, it can become more
difficult to explain unexpected results and identify
errors. Similarly, given the constrained resources and
short timeframe commonly available for modelling
applications, if the model runs slowly and requires
substantial computing resources, this can limit the
opportunities to fully investigate parameter uncer-
tainty, assess different scenarios and iteratively
improve the analysis through feedback from model-
ling stakeholders.
Table 1 Principles for country-level TB modelling
1 Relevance: modelling should assess the policies and outcomes
relevant to the decision-maker
2 Realism: modelling should explicitly consider implementation
challenges that may reduce the effectiveness or increase the
costs of interventions when introduced into routine
practice, and examine the plausibility of assumptions
required for policy success
3 Appropriateness of model structure: the model design should
be justified in terms of the questions and local context being
considered—the structure should be sufficiently detailed to
represent the mechanisms generating outcomes, but avoid
unnecessary complexity
4 Consideration of all evidence: modelling should consider all
available evidence relevant to the decision problem
5 Validation: where possible, model results should be compared
with evidence not used for model parameterisation or
calibration to understand the consistency of modelling
results with other evidence
6 Informativeness: modelled analyses should report a rich set of
results describing consequences for a range of outputs and
outcomes to provide a deeper understanding of the
scenarios being modelled and model functioning
7 Transparency: modelling results should be accompanied by a
clear description of the evidence that supports the main
findings, limitations of the modelling approach, uncertainty
in modelled estimates and the sensitivity of results to
different assumptions. Conflicts of interest should be
avoided if possible, or otherwise described explicitly
8 Timeliness: modelling activities should be organised to provide
results at the time they are required for decision-making
9 Country ownership: modelling should be conducted with the
full participation of local stakeholders at each stage of the
process
10 Iteration: modelling should involve an iterative process of
engagement and be reconsidered in the light of new
evidence
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Principle 4: consideration of all evidence
Modelling should consider all available evidence
relevant to the decision problem. Mathematical
models specify a sequence of relationships linking
the actions described under a policy scenario to the
health and economic outcomes of interest. Typically,
many different evidence sources are required to
parameterise these relationships, and errors in any
of these parameters could affect results. While there
will be finite time and resources available to collate
inputs, all key data and evidence should be identified
and incorporated to produce valid and accurate
results. Where there is substantial uncertainty in key
parameter inputs, this uncertainty should be thor-
oughly investigated, and the implications reported
alongside the main analytic results. Adjusting param-
eter values so that model predictions are consistent
with observed data (model calibration) can improve
the validity of future projections and increase
confidence among consumers in modelling results.
However, calibration should be undertaken carefully
to avoid over-fitting and acknowledge potential
biases in calibration data.
Principle 5: validation
Where possible, model results should be compared
Figure Flow chart of steps involved in a typical modelling project*. * Numbers refer to principles
described in the text. Icons shown on right of the figure describe suggested lead actors for each
step in the modelling process, i.e., the individual or group primarily responsible for implementing
principles from a given practice. Actors include in-country decision makers ( ), in-country experts
( ), modellers ( ) and international funders ( ). Other actors may also have a role in contributing
towards activities or in creating the demand for them.
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with evidence not used for model parameterisation or
calibration to understand the consistency of model-
ling results with other evidence. Given the complexity
and number of assumptions involved in mathematical
models, it is difficult to confirm that the model will
produce valid results by scrutinising model inputs and
structure. Further evidence that a model is reasonable
can be gained by comparing model outputs to
external estimates for these outputs. Sources of these
estimates could include the results of empirical
studies, similar modelling efforts or the experience
of subject matter experts. None of these comparisons
can guarantee that the results of an analysis are valid,
but instead provide confirmation that some aspects of
model predictions are consistent with external data,
or alternately reveal conflicts for further investiga-
tion.
Principle 6: informativeness
Modelled analyses should report a rich set of results
describing a range of outputs and outcomes to
provide a deeper understanding of policy scenarios
and model functioning.
TB policy or planning options will likely have
implications for a range of different outcomes of
interest to decision makers. For example, an inter-
vention that improves the quality of TB care in
marginalised communities will most immediately
reduce morbidity and mortality in individuals with
active TB disease, but could also have implications
forMycobacterium tuberculosis transmission and TB
incidence, trends in TB drug resistance and the socio-
economic distribution of TB burden. In conventional
economic evaluation, these various outcomes are
combined in a single measure of health benefit—such
as disability-adjusted life-years (DALYs) averted or
deaths averted—to summarise the overall health
implications of a policy. Calculating a single summa-
ry metric facilitates the process of identifying optimal
choices (e.g., policies that maximise health benefits
for a given budget envelope).
Nonetheless, summary measures may not capture
all health outcomes of interest to decision makers. For
example, although total DALYs or deaths averted will
not describe the distribution of health benefits across
the population, such distributional information is
relevant if reducing inequality is a policy goal.
Reporting results for multiple outputs and outcomes
can provide a more complete description of policy
consequences. Moreover, providing a rich set of
results can help decision makers develop a deeper
understanding of how interventions work, how
different outcomes relate to each other and the timing
of effects. Similar considerations apply to resource
needs estimates. While an estimate of total resource
needs is often required, it is also useful to provide cost
estimates disaggregated according to when resources
are needed, what budget they draw on and how they
compare with existing expenditures. Finally, report-
ing a more informative set of results can facilitate
additional reality checks, allowing modelling partic-
ipants to confirm that anticipated programme chang-
es are plausible.
Principle 7: transparency
Modelling results should be accompanied by a
description of the evidence that supports main
findings, limitations of the modelling approach,
uncertainty in modelled estimates and the sensitivity
of results to different assumptions. Conflicts of
interest should be avoided if possible, or otherwise
described explicitly. Models typically reach a level of
complexity that makes their mechanisms difficult to
understand for anyone lacking the necessary time to
read and review extensive documentation, particu-
larly stakeholders who are less familiar with model-
ling methods. Modelling commonly requires
assumptions that have only weak empirical support,
yet due to the sheer number of assumptions being
made it is difficult for a consumer of modelling results
to know which assumptions are important and which
have only a minor influence on the outcomes of
interest. Nevertheless, it is critical that consumers of
modelling results have the information available to
understand the strengths and limitations of modelling
results, and main threats to validity.
The fact that modelled analyses are complicated
and subject to many analytic decisions means that
conflicts of interest can be particularly problematic.
Conflicts may arise where there are significant
commercial, professional, political or other interests
involved in a particular decision. If analytic ap-
proaches are chosen to favour a preferred outcome,
this may not be apparent to a non-expert audience, or
even an expert audience aware of the range of
possible modelling approaches. For this reason,
important conflicts of interest among the participants
in a modelling process should be identified and
avoided where possible. It may not always be possible
to avoid conflicts, in which case an explicit statement
describing the conflicts should accompany the results.
Principle 8: timeliness
Modelling activities should be organised to provide
results at the time they are required for decision-
making. Ideally, this principle would not conflict with
the other principles. However, in practice the need to
produce results quickly can reduce the opportunities
to test all aspects of a model, and can reduce the time
and opportunities for stakeholders to review results,
raise questions and refine scenarios. Allowing for a
sufficient lead-in time in the policy planning process
should help alleviate potential conflicts between this
and the other principles.
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Principle 9: country ownership
Modelling should be conducted with the full partic-
ipation of local stakeholders at each stage of the
process. Modelling is more likely to be useful when
conducted with the full participation of relevant
stakeholders. Their involvement means that model-
ling assumptions and modelled scenarios are more
likely to be appropriate, and that results are fully
understood and considered by policy makers when
making decisions. Country ownership is not guaran-
teed in situations where modelling is conducted by
external technical experts, and where the need for
format of the modelling exercise are driven by
external funding agencies. In these situations, greater
effort may be needed to fully engage important
stakeholders. In any country, there will be existing
initiatives for the collection and use of data to inform
programme planning. Coordination with these efforts
will improve the quality of data available for
modelling, and reduce the chance that decision
makers receive conflicting policy advice.
Principle 10: iteration
Modelling should involve an iterative process of
engagement, and be reconsidered in the light of new
evidence. Given the complexity of modelling and
decision-making, the process of identifying candidate
policies or interventions, and the evidence to describe
them, is likely to be iterative. It is important that the
modelling approach allows for this iteration between
adaptation of the model and evaluation of results.
After a modelling exercise is complete, the results
should remain open to criticism and revision in light
of new evidence, and a clear way forward to
improving the process should be identified.
DISCUSSION
The use of mathematical modelling to support TB
policy making has been encouraged by major funders
and adopted by several high-burden countries. These
quantitative planning exercises can provide evidence
on proposed interventions, support funding applica-
tions and improve the impact of limited resources.
The country-level TB modelling guidance was devel-
oped to provide a framework—as well as pragmatic
advice—for how TB modelling and related technical
assistance can support country decision-making.26
The principles described in this guidance cover the
design and estimation of the mathematical models
themselves, as well as methods for identifying and
synthesising evidence, and approaches for incorpo-
rating modelling into country decision-making. These
principles serve three higher-level goals: 1) that
model-informed policy evaluation makes the best
use of available evidence, 2) that modelling is
incorporated into policy making in a way that clearly
recognises the strengths and weaknesses of modelled
estimates, and 3) that modelling supports (rather than
replaces) policy making as a deliberative, country-led
process.
The process of developing this guidance revealed
several challenges facing country-level TB modelling
(Table 2). A number of these challenges can be
addressed in the context of an individual modelling
application, and are addressed in the guidance. For
example, the guidance speaks clearly on the need to
anticipate implementation challenges that could
reduce effectiveness or increase costs for novel
policies to achieve more credible projections. The
guidance is also clear on the need to transparently
describe the evidence base supporting a policy
projection and how weaknesses in this evidence could
affect policy recommendations, so that users can
weigh the robustness of policy decisions based on the
modelling results.
Other challenges will be difficult to resolve in an
individual application, but are amenable to ongoing
changes in the practice of modelling. The difficulty of
adapting models to reflect individual country settings
and policy preferences is a consequence of the current
modelling paradigm, where a modelling application
typically involves an international technical assis-
tance provider tailoring a generic model to answer
country-specific policy questions.6 This process often
occurs over a short period of time and can require
approximations that might be reasonable, given the
imperative to answer urgent policy questions, but
that still leaves room for improvement. As modelling
becomes more commonplace, country needs are likely
to be better understood before an application begins,
reducing the need for short-term approximations.
Table 2 Challenges for country-level TB modelling identified
during guidance development process
1 Limitations in the data and evidence available to inform
modelled analyses
2 Limitations in the ability of models to represent complex policy
scenarios, such as targeting of risk groups not represented
in existing models
3 Difficulty in anticipating factors that could negatively impact
the outcomes of modelled policy scenarios, such as those
that involve novel interventions or aggressive expansion of
existing services
4 Difficulty in describing the uncertainty in modelled results and
how this should impact decision-making
5 Differences in the modelling and estimation approaches taken
by modelling teams, with the potential that different
models could provide different policy advice, given the same
country context and policy question
6 Scarcity of human resources (worldwide and within high-
burden countries) to meet the demand for modelling
technical assistance, and lack of information for country TB
programmes on what modelling support is available
7 Differences in the level of experience, understanding or
expectations of the modelling process by in-country
stakeholders and international funders, and related to this,
difference in the confidence placed in modelled analyses by
local and international stakeholders
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The natural progression of this is institutionalisation
of modelling within countries, as is happening in
South Africa.5 Such institutionalisation requires
sustained investments in capacity building. As a
result of these efforts, models are better prepared to
answer policy questions when needed, and decision
makers better understand how to interpret modelling
evidence. Such institutionalisation may not be possi-
ble for all countries, but repeated exposure of
decision makers to modelling evidence—and repeated
exposure of modellers to decision makers and new
policy questions—will mean that all participants in a
modelling application start the application better
prepared and become more thoughtful consumers of
the results of these applications.
Another challenge is the difficulty of validating
models. In almost all cases, the modelling results used
for decision-making, such as projections of long-term
outcomes, and incremental cost-effectiveness ratios,
cannot be validated directly, as the empirical infor-
mation to do so may never be available. Moreover, as
many threats to validity will be specific to an
individual setting and policy question, a model
cannot itself be considered ‘valid’ separate from the
details of how it is used in an individual application.
These facts provide a partial explanation for the
variable results produced by model comparison
exercises. However, intermediate outcomes, such as
descriptions of current epidemiology and programme
functioning, are more amenable to validation. Future
efforts to facilitate the validation of intermediate
outcomes could strengthen the quality of modelling
evidence and reduce variation that is inconsistent
with available empirical evidence. Even for outcomes
where empirical information is weak, such as the
prevalence of latent tuberculous infection, the force
of infection and the proportion of incident disease
due to recent infection, routine collection of estimates
generated during modelling exercises could provide
broader insight into model functioning, and explain
divergent modelling results. While requiring substan-
tial time and effort, model comparison exercises are
invaluable for investigating where and why models
differ, and facilitating knowledge sharing between
modelling groups.
One challenge—weaknesses in the evidence used
for modelling—may require action beyond the
traditional participants in policy modelling. While
the evidence for modelling will always be imperfect,
the process of developing this guidance identified
several critical evidence gaps. Central among these
was evidence on the effectiveness of approaches to
improve the coverage and quality of existing TB
interventions. These incremental programme im-
provements are less likely to be considered in formal
trials, but are central to efforts to strengthen TB
control. For current modelling applications, this
evidence gap is commonly filled by expert opinion.
While this may be a practical solution given the time
constraints of a typical modelling application, it
introduces uncertainty and subjectivity for a key
determinant of policy impact. Modelling would
benefit from additional efforts to collect and synthe-
sise empirical data on policy costs and effects, and
understand health system and programmatic con-
straints.27 During the development of this guidance,
there was discussion about whether modellers should
ever refuse to report results for policy scenarios where
evidence is weak. It was decided not to include this in
the guidance, but the incentives for modellers to
report their best estimates for the questions posed to
them, and the potential for policy makers to make
decisions based on point estimates reported from
these analyses, means that data limitations may be
difficult to identify when reviewing modelling results,
and thus underappreciated. Even where uncertainty is
reported, methods are not well developed for
supporting decision makers to act on this informa-
tion.
CONCLUSION
Modelling is an unavoidable consequence of the
desire to understand the future impact of policy
choices. Predicting policy outcomes can be accom-
plished by using a formal mathematical model, by
direct extrapolation from local empirical studies,
generalising from similar programmes or countries or
by relying on expert opinion. Each of these approach-
es requires assumptions that should be evaluated
critically. None of these approaches can dispel the
epistemic uncertainty inherent in policy making, but a
desirable approach will transparently communicate
the uncertainties associated with analytic results, and
demonstrate their implications for decision-making.
Transparency about the uncertainty in modelling
results will also incentivise efforts to collect and
synthesise empirical data on policy costs and effects,
and to understand how health system and program-
matic constraints should be reflected in modelled
analyses.24
If adopted, the guidance we have described will
improve the quality and utility of modelling. To
support this process, TB MAC and modelling
stakeholders are developing tools and processes to
facilitate the implementation of the guidance for
routine modelling work. This involves the develop-
ment of quantitative benchmarks for model valida-
tion, standardised reporting formats to demonstrate
good practices were followed and a mechanism to
provide independent expert review of modelling
applications. Taken together, these benchmarking,
reporting and reviewing activities will provide tools
to reveal where a given modelling application is
inconsistent with existing evidence or best-practice
modelling approaches. If routinely applied, these
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tools could strengthen the incentives for high-quality
modelling work, and tighten the link between
modelling results and the evidence used to justify
them, supporting the ongoing improvement of
modelling as an aid for country-level TB decision-
making.
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R E´ S U M E´
La mode´lisation mathe´matique est habituellement
utilise´e pour e´valuer les options de politiques en
matie`re de lutte contre la tuberculose (TB) dans les
pays fortement touche´s. Les de´cisions majeures en
matie`re de politique et de financement sont prises en
fonction de ces analyses, mais la variabilite´ des re´sultats
produits par les analyses de politique mode´lise´es reste
pre´occupante. Nous discutons d’une nouvelle guidance
pour la mode´lisation de la politique relative a` la TB dans
chaque pays. La guidance a e´te´ de´veloppe´ par le TB
Modelling and Analysis Consortium en collaboration
avec la programme mondial TB de l’Organisation
Mondiale de la Sante´, avec la participation d’un range
d’acteurs de la TB (financeurs, groupe de mode´lisation,
personnel du programme TB national et experts du
domaine). La guidance de´crit les principes de la
mode´lisation de la TB dans les pays ainsi que les
bonnes pratiques de mise en œuvre des principes. Les
principes couvrent les questions techniques comme la
conception du mode`le, le parame´trage et la validation,
ainsi que les approches visant a` incorporer la
mode´lisation dans les de´cisions politiques des pays et le
financement. Pour les mode´lisateurs, cette guidance
sugge`re des approches visant a` ame´liorer la qualite´ et
la pertinence de la mode´lisation entreprise afin de
soutenir la planification au niveau des pays. Pour les
non mode´lisateurs, cette guidance de´crit les e´le´ments a`
envisager pour engager une assistance technique en
termes de mode´lisation, contribuant a` un exercice de
mode´lisation, ou a` revoir les re´sultats des analyses
mode´lise´es. Si elle est adopte´e en routine, cette guidance
devrait ame´liorer la fiabilite´, la transparence et l’utilite´
de la mode´lisation pour les prises de de´cisions en matie`re
de TB au niveau des pays. Cette guidance ne re´soudra
cependant pas tous les de´fis de la mode´lisation et un
travail continu est requis pour ame´liorer la base de
preuves concre`tes afin d’e´valuer les politiques en matie`re
de TB et de de´velopper des me´canismes plus solides de
validation des mode`les. Augmenter l’appropriation par
les pays des processus de mode´lisation reste un de´fi,
exigeant un engagement soutenu et un renforcement des
capacite´s.
R E S UM E N
La modelizacio´n matema´tica se suele utilizar con el fin
de evaluar las opciones de las polı´ticas de control de la
tuberculosis (TB) en los paı´ses con alta carga de
morbilidad. Las principales decisiones normativas y de
financiamiento se adoptan en funcio´n de estos ana´lisis;
sin embargo, es preocupante observar la variabilidad de
los resultados de los ana´lisis modelizados de las
polı´ticas. En el presente estudio se examina una nueva
orientacio´n en materia de modelizacio´n a escala
nacional de las polı´ticas contra la TB. El TB
Modelling and Analysis Consortium elaboro´ las
directrices en colaboracio´n con el Programa Mundial
contra la Tuberculosis de la Organizacio´n de la Salud,
con aportaciones de una diversidad de interesados
directos en la TB (financiadores, grupos de
modelizacio´n, personal de Programas Nacionales
contra la TB y expertos en el tema). La orientacio´n
describe los principios de la modelizacio´n a escala
nacional, adema´s de las pra´cticas adecuadas para
ponerlos en pra´ctica. Los principios abordan
prioridades te´cnicas como el disen˜o del modelo, la
parametrizacio´n y la validacio´n y tambie´n me´todos
encaminados a incorporar la modelizacio´n en la
formulacio´n de polı´ticas y la elaboracio´n de
presupuestos dirigidas por los paı´ses. Estas
orientaciones ofrecen a los modelizadores me´todos
para mejorar la calidad y la pertinencia de la
modelizacio´n que emprenden con el fin de respaldar la
planificacio´n nacional. A otras personas que no
participan en la elaboracio´n de modelos, la orientacio´n
describe aspectos que se deben tener en cuenta al
solicitar asistencia te´cnica con la modelizacio´n,
participar en un ejercicio de modelizacio´n o evaluar los
resultados de los ana´lisis modelizados. Esta orientacio´n,
una vez adoptada de manera sistema´tica, deberı´a
mejorar la fiabilidad, la transparencia y la utilidad de
la modelizacio´n en la formulacio´n de las polı´ticas
nacionales en materia de TB. Sin embargo, el
documento no aborda todas las dificultades que surgen
durante la modelizacio´n y se precisan esfuerzos
continuos que mejoren la base de datos probatorios
para la evaluacio´n de las polı´ticas relacionadas con la
TB y la creacio´n de mecanismos ma´s so´lidos de
validacio´n de los modelos. Lograr una mayor
apropiacio´n nacional del proceso de modelizacio´n
sigue siendo una empresa difı´cil, que exige un
compromiso permanente y fortalecimiento de la
capacidad.
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